Nplate

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
17-10-2022
Valmisteyhteenveto Valmisteyhteenveto (SPC)
17-10-2022

Aktiivinen ainesosa:

romiplostim

Saatavilla:

Amgen Europe B.V.

ATC-koodi:

B02BX04

INN (Kansainvälinen yleisnimi):

romiplostim

Terapeuttinen ryhmä:

Antihemorrhagics

Terapeuttinen alue:

Purpura, Thrombocytopenic, Idiopathic

Käyttöaiheet:

Adults:Nplate is indicated for the treatment of primary immune thrombocytopenia  (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Paediatrics:Nplate is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Tuoteyhteenveto:

Revision: 26

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2009-02-04

Pakkausseloste

                                77
B. PACKAGE LEAFLET
78
PACKAGE LEAFLET: INFORMATION FOR THE USER
NPLATE 125 MICROGRAMS POWDER FOR SOLUTION FOR INJECTION
NPLATE 250 MICROGRAMS POWDER FOR SOLUTION FOR INJECTION
NPLATE 500 MICROGRAMS POWDER FOR SOLUTION FOR INJECTION
Romiplostim
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Nplate is and what it is used for
2.
What you need to know before you use Nplate
3.
How to use Nplate
4.
Possible side effects
5.
How to store Nplate
6.
Contents of the pack and other information
1.
WHAT NPLATE IS AND WHAT IT IS USED FOR
Nplate’s active ingredient is romiplostim, which is a protein used
to treat low platelet counts in
patients with immune primary thrombocytopenia (called ITP). ITP is a
disease in which your body’s
immune system destroys its own platelets. Platelets are the cells in
your blood that help seal cuts and
form blood clots. Very low platelet counts can cause bruising and
serious bleeding.
Nplate is used to treat adult patients with ITP who may or may not
have had their spleen removed and
who have been previously treated with corticosteroids or
immunoglobulins, where these treatments
don’t work. Nplate is also used to treat children aged 1 year and
over with chronic ITP who may or
may not have had their spleen removed and who have been previously
treated with corticosteroids or
immunoglobulins, where these treatments don’t work.
Nplate works by stimulating the bone marrow (part of the bone which
makes blood cells) to produce
more platelets. This should help to
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Nplate 125 micrograms powder for solution for injection
Nplate 250 micrograms powder for solution for injection
Nplate 500 micrograms powder for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Nplate 125 micrograms powder for solution for injection
Each vial contains 125 mcg of romiplostim. After reconstitution, a
deliverable volume of 0.25 mL
solution contains 125 mcg of romiplostim (500 mcg/mL). An additional
overfill is included in each
vial to ensure that 125 mcg of romiplostim can be delivered.
Nplate 250 micrograms powder for solution for injection
Each vial contains 250 mcg of romiplostim. After reconstitution, a
deliverable volume of 0.5 mL
solution contains 250 mcg of romiplostim (500 mcg/mL). An additional
overfill is included in each
vial to ensure that 250 mcg of romiplostim can be delivered.
Nplate 500 micrograms powder for solution for injection
Each vial contains 500 mcg of romiplostim. After reconstitution, a
deliverable volume of 1 mL
solution contains 500 mcg of romiplostim (500 mcg/mL). An additional
overfill is included in each
vial to ensure that 500 mcg of romiplostim can be delivered.
Romiplostim is produced by recombinant DNA technology in _Escherichia
coli_ (_E. coli_).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for injection (powder for injection).
The powder is white.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Adults:
Nplate is indicated for the treatment of primary immune
thrombocytopenia (ITP) in adult patients who
are refractory to other treatments (e.g. corticosteroids,
immunoglobulins) (see sections 4.2 and 5.1).
Paediatrics:
Nplate is indicated for the treatment of chronic primary immune
thrombocytopenia (ITP) in paediatric
patients one year of age and older who are refractory to other
treatments (e.g. corticosteroids,
immunoglobulins) (see sections 4.2 and 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment should rema
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto bulgaria 17-10-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 01-06-2018
Pakkausseloste Pakkausseloste espanja 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto espanja 17-10-2022
Pakkausseloste Pakkausseloste tšekki 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto tšekki 17-10-2022
Pakkausseloste Pakkausseloste tanska 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto tanska 17-10-2022
Pakkausseloste Pakkausseloste saksa 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto saksa 17-10-2022
Pakkausseloste Pakkausseloste viro 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto viro 17-10-2022
Pakkausseloste Pakkausseloste kreikka 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto kreikka 17-10-2022
Pakkausseloste Pakkausseloste ranska 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto ranska 17-10-2022
Pakkausseloste Pakkausseloste italia 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto italia 17-10-2022
Pakkausseloste Pakkausseloste latvia 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto latvia 17-10-2022
Pakkausseloste Pakkausseloste liettua 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto liettua 17-10-2022
Pakkausseloste Pakkausseloste unkari 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto unkari 17-10-2022
Pakkausseloste Pakkausseloste malta 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto malta 17-10-2022
Pakkausseloste Pakkausseloste hollanti 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto hollanti 17-10-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 01-06-2018
Pakkausseloste Pakkausseloste puola 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto puola 17-10-2022
Pakkausseloste Pakkausseloste portugali 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto portugali 17-10-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 01-06-2018
Pakkausseloste Pakkausseloste romania 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto romania 17-10-2022
Pakkausseloste Pakkausseloste slovakki 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto slovakki 17-10-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 01-06-2018
Pakkausseloste Pakkausseloste sloveeni 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto sloveeni 17-10-2022
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 01-06-2018
Pakkausseloste Pakkausseloste suomi 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto suomi 17-10-2022
Pakkausseloste Pakkausseloste ruotsi 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto ruotsi 17-10-2022
Pakkausseloste Pakkausseloste norja 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto norja 17-10-2022
Pakkausseloste Pakkausseloste islanti 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto islanti 17-10-2022
Pakkausseloste Pakkausseloste kroatia 17-10-2022
Valmisteyhteenveto Valmisteyhteenveto kroatia 17-10-2022

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia